This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad to End Development of Flurizan

Myriad Genetics (MYGN - Get Report) said Monday that it will stop development of its experimental Alzheimer's disease drug Flurizan due to the failure of a pivotal phase III study.

The Flurizan study, which enrolled patients with mild to moderate Alzheimer's, did not achieve statistical significance on either of its two primary endpoints -- cognition or activities of daily living, the company said.

While disappointing, the negative outcome from the Flurizan study was not unexpected, given the relatively poor results coming out of the drug's phase II study. In fact, many investors are likely to welcome Flurizan's demise because shelving the drug will reduce Myriad's expenses and boost profits from the company's genetics testing business.

Myriad shares were up 15 cents, or 0.3%, at $47.85 in premarket trading Monday.

"The discontinuation of Flurizan will reduce our pharmaceutical development spend substantially and should enable Myriad to achieve profitability next year," said CEO Peter Meldrum, referring to the fiscal year ending June 30, 2009.

Myriad says it spent $60 million on Flurizan's development already and will spend another $8 million to wrap up the clinical work. But Myriad was able to recoup these costs in May when it signed away European rights for Flurizan to Danish drug maker Lundbeck. As part of that agreement, Lundbeck paid Myriad $100 million.

Consensus estimate calls for Myriad to lose 52 cents a share on $234 million in revenue the 2008 fiscal year ending today. Next year, the company is expected to earn 35 cents on revenue of $315 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
MYGN $34.55 1.10%
AAPL $128.73 -0.17%
FB $78.81 -0.23%
GOOG $540.66 0.51%
TSLA $230.65 2.00%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs